News | August 12, 2009

FDA Medical Device, Radiological Health Regulator Resigns

Daniel Schultz, M.D., director of the FDA Center for Devices and Radiological Health

August 12, 2009 - The Food and Drug Administration's (FDA) top medical-device regulator, Daniel Schultz, M.D., director of the FDA Center for Devices and Radiological Health, announced his resignation.

While Dr. Schultz said it was a mutual agreement with FDA Commissioner Margaret Hamburg, the decision followed internal dissent over device-approval decisions that the regulator's critics said were too friendly to industry.

Dr. Schultz has worked at the FDA's Center for Devices and Radiological Health for 15 years and led it for the past five years. However, concerns over Dr. Schultz’s decisions surfaced two years ago when Sen. Chuck Grassley (R- Iowa) held hearings on Dr. Schultz's approval of a nerve stimulation device to treat depression, irrespective of objections from multiple FDA doctors. The senator again opened an investigation into a knee-surgery device made by ReGen Biologics Inc., also approved by Dr. Schultz despite numerous objections from FDA scientists and reviewers.

A year ago, the House Energy and Commerce Committee launched an investigation into allegations by at least eight FDA scientists that agency managers coerced those in the medical device division into approving products despite serious safety and effectiveness concerns.

The investigation was prompted by a letter released publicly from “a large group of scientists and physicians” within the FDA's Center for Devices and Radiological Health (CDRH), dated Oct. 14, 2008, said Committee Chair John Dingell (D-Mich.) and Oversight and Investigations Subcommittee Chair Bart Stupak (D-Mich.) According to the statement, the letter describes CDRH managers that have “corrupted and interfered with the scientific review of medical devices.”

The statement went on to say that the committee has been “provided with compelling evidence to support the charges that senior managers within CDRH ‘ordered, intimidated and coerced FDA experts to modify their scientific reviews, conclusions and recommendations in violation of the law.'”

The scientists claim that they were threatened with removal or negative performance reviews if they did not modify their scientific data to obscure unscientific clinical and technical data submitted by device companies and legal violations, including a lack of informed consent from study participants.

For more information: www.fda.gov

Related Content

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve). Photo by Greg Freiherr

Feature | Cardiac Imaging | March 22, 2019 | By Greg Freiherr
Reflecting a trend toward the increased use of ...
SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

Feature | Cardiac Imaging | March 18, 2019 | By Greg Freiherr
As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the
Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Feature | Cardiac Imaging | March 17, 2019 | By Greg Freiherr
Virtual reality (VR) and its less immersive kin, augmented reality (AR), are gaining traction in some medical applica
WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography.

WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography. Photo by Greg Freiherr

Feature | Cardiac Imaging | March 16, 2019 | By Greg Freiherr
Machine learning is already having an enormous impact on cardiology, automatically calculating measurements in echoca
Podcast | Cardiac Imaging | March 15, 2019
Debate About Coronary Testing Highlights ACC Session

Collage depicts broad applications in machine learning or deep learning (DL) that can be applied to advanced medical imaging technologies. Size of the liver and its fat fraction — 22 percent — (top middle in collage) can be quantified automatically using an algorithm developed by Dr. Albert Hsiao and his team at the University of California San Diego. This and other information that might be mined by DL algorithms from CT and MR images could help personalize patients’ treatment. Collage provided by Albert Hsiao

Feature | Cardiac Imaging | March 12, 2019 | By Greg Freiherr
Acquiring these data could change patient management
Podcast | Cardiac Imaging | March 12, 2019
How smart algorithms might reduce the burden of modern practice
Podcast | Cardiac Imaging | March 08, 2019
Why CT angiography cannot replace invasive angiography
Podcast | Cardiac Imaging | March 04, 2019
AI, Mobile Technologies Are Changing How We Think About Cardiac Disease
Videos | Cardiac Imaging | September 10, 2018
Leslee Shaw, Ph.D., professor of cardiology and rad
Overlay Init